Inhaled nitric oxide significantly reduced pulmonary vascular resistance at 30 minutes compared to conventional therapy alone in patients with acute severe right heart failure and pulmonary hypertension.
Does inhaled nitric oxide (iNO) improve pulmonary vascular resistance in patients with acute severe right heart failure associated with pulmonary hypertension?
Inhaled nitric oxide safely and effectively reduces pulmonary vascular resistance and improves surrogate markers of right heart failure in patients with pulmonary hypertension, filling a long-standing evidence gap.
including inotropes, vasopressors, and oxygen administration, is being used to optimize preload, afterload, and cardiac contractility (Figure ). 1,5However, there is a lack of high-quality evidence regarding pharmacological strategy during the acute phase for pulmonary vasodilators D ecompensated acute right heart failure (RHF) is one of the most severe complications pulmonary hypertension (PH). 1 Despite recent progress in disease-specific treatment, such as selective pulmonary vasodilators and balloon pulmonary angioplasty, 2-4 patients with acute RHF due to PH have high morbidity and mortality rates.Most of these patients require intensive care, but therapeutic options remain limited.Supportive therapy,
Tatebe et al. (Fri,) conducted a editorial in Acute severe right heart failure associated with pulmonary hypertension (n=30). Inhaled nitric oxide (iNO) vs. Conventional PH therapy alone was evaluated on Change in pulmonary vascular resistance (PVR) from baseline to 30 minutes. Inhaled nitric oxide significantly reduced pulmonary vascular resistance at 30 minutes compared to conventional therapy alone in patients with acute severe right heart failure and pulmonary hypertension.